Common Stock, par value $0.0001 per share
- Symbol
- VBIO
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Valion Bio, Inc.
VBIONASDAQEQUITYCurrent
Other Events
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Description Number ───────────────────────────────────────────────────────────────────────────────────────────── 99.1 Press Release, dated October 14, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
Press release in this filing
With Section 232 Tariffs Reshaping Biotech, Valion Bio’s Velocity Bioworks Capitalizes on Domestic CDMO Surge →Company context
We are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act. An emerging growth company may take advantage of specified reduced reporting requirements that are otherwise generally applicable to public companies. As a result:
Current securities
Historical securities (1)
Registered securities in this filing
Valion Bio, Inc. · 8-K · Filed 2026-10-14
Disclosure sections
Item 9.01Item 9.01 - Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Description
Number
─────────────────────────────────────────────────────────────────────────────────────────────
99.1 Press Release, dated October 14, 2026.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).